Profit before payment of interest, taxes and amortization: intelliatx.com (NTLA)
Intellia Therapeutics (NTLA) develops innovative treatments for hereditary pathologies. On GURU.Markets, the EBITDA trend visualizes the scaling potential of gene therapy, where the current status is 0.00. Business stability relies on the ownership of CRISPR patents and a strong scientific foundation. Meanwhile, the company's success is based on R&D pipeline results and strict control over the expenditure of existing cash reserves.
Intellia Therapeutics, Inc. - analytical breakdowns and key metrics (NTLA)
- stock price and consensus target price:
- company stock exchange capitalization indicators:
- business book valuation details:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Intellia Therapeutics|NTLA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Intellia Therapeutics Inc|NTLA - Company Aggregate Debts|Debt to Net Assets Ratio Intellia Therapeutics|NTLA - Company Long-Term Debts|Short-Term Debt Intellia Therapeutics|Intermediate Coverage Ratio intelliatx.com
- company profitability and valuation multiples indicators:
NTLA - Net Profit|Projected Future Earnings Intellia Therapeutics|NTLA - Price to Earnings Ratio|Price to Expected Earnings Ratio intelliatx.com|NTLA - PEG Multiple|Company Value to EBITDA Intellia Therapeutics|NTLA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Intellia Therapeutics|NTLA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months intelliatx.com|NTLA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Intellia Therapeutics
- sales revenue and business income indicators:
Summary company analytics:Intellia Corp
Intellia Therapeutics (NTLA) is developing high-risk CRISPR technologies, where the lack of profitability depends on the outcome of clinical trials. This indicator measures the actual cash flow from core operations before depreciation and interest. Negative values signal high development costs and a reliance on external financing. Investors should assess the burn rate via the annual EBITDA figure. This chart reflects the efficiency of cost management under regulatory pressure.
Who Intellia Therapeutics competes with
Tempus - Profit before payment of interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS: Profit before payment of interest, taxes and amortization|RGEN: Operating profit EBITDA|RNA - Operating income before deduction of amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Operating profit EBITDA GeneDx Corp|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Sarepta - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization TWST (Twist Bioscience Inc)|10x Genomics Corp - Operating profit EBITDA|Income before deduction of interest, taxes and amortization STOK (Stoke Corp)|BLFS: Operating profit EBITDA|Profit before interest, taxes and amortization wavelifesciences.com (WVE)|Profit before payment of interest, taxes and amortization Maze Therapeutics|SION: Income before deduction of interest, taxes and amortization|Operating profit EBITDA PRME|Operating profit EBITDA Taysha Corp (TSHA)|Profit before payment of interest, taxes and amortization uniQure N.V. QURE|MGTX (meiragtx.com) - Profit before deduction of interest, taxes, depreciation and amortization|REGENXBIO - Operating profit EBITDA|Profit before interest, taxes and amortization Solid Biosciences Inc|OCGN (Ocugen Corp) - Operating profit before deduction of amortization|PacBio Corp (PACB) - Operating profit EBITDA|Operating profit before deduction of amortization BNTC|DSGN (designtx.com) - Company profit before taxes, interest and amortization|Operating profit EBITDA RCKT|Operating income before deduction of amortization 4DMT|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|KRRO - Operating profit before deduction of amortization|EDIT - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization silence-therapeutics.com SLN|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CDXS|Operating profit before deduction of amortization SGMO|NAUT (Nautilus Biotechnology Inc) - Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|Profit before payment of interest, taxes and amortization DTIL (precisionbiosciences.com)|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|Exicure Corp - Operating profit EBITDA|IMNN (Imunon, Inc.) - Operating profit before amortization|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MBIO|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Bionano|Operating profit EBITDA APDN|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|OMGA: Operating profit before amortization|OMIC: Operating profit before deduction of amortization|Regulus Therapeutics, Inc. - Company profit before taxes, interest and amortization|SYRS: Operating profit EBITDA|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Profit before payment of interest, taxes and amortization UBX
